Shanghai Henlius Biotech, Inc. Class H · HKEX:2696

Shanghai Henlius Biotech, Inc. Class H — FY2024 Earnings Presentation

47 slides from Shanghai Henlius Biotech, Inc. Class H's earnings presentation, Mar 24, 2025

1. Slide 1: 2024年度业绩推介

   ‫࠯؏ו‬望ͣ2696.HKͤ 2024‫څٵ‬Ў働 2025‫ٶ‬3߃ © 2025 Henlius.

2. Slide 2: 2024年度业绩亮点

   01 2024‫ٵ‬Ў働ш䎯Ղҷ՚‫ࣛی‬ © 2025 Henlius.

3. Slide 3: 2024业绩亮点

   2024Ў働ࠃ੒͵㔀‫ݗ‬Ҵ57.2ыͧӓӮ䃂૖8.2ы 㔀‫ݗ‬Ҵ ֋Ԇ‫ى܃‬ ֧ऒॡ঎ ֋ЎԖ㔀уৗ কਗࢻଟࡗ 57.2ы 4஍ ι50஍ 48KL 12.4ы ֋ЎԖ BD R&D ࣏у એԆ • ੧Џ௅үङ୦։঒ࣲѽ঩չ௤働 • ݉еDr. Reddy’s HLX15जЈࡨ • ࡎ‫®ࣙގ‬йࠬनੂ‫܅‬Ї١ͫީ௙ • ‫ׂ֪ࡍڰ‬Њߠ㿄ׂ֪ͧ▲ͨ֌Џ • 2024‫ݶۈٶ‬ҵ57.2ьҫͫգࡁ‫׍‬ ‫ݼ‬澝௤‫ۼ‬੧ԃङ୦։֝஄ͫ‫ؘ࣫‬ ‫ذ‬չலਉࡨ‫ذ‬Дय़ӷֺ֨২֢Ճ ЗЌ֊▲֨ࠬनੂ‫܅‬Ї١ऀй ԗGMPࣿф‫ࠩ܅‬૝1000‫ࣿͫ܅‬ ୸6.1% ҡ‫ډ‬չՕܴ৒

4. Slide 4: Biopharma strategy and business model

   ࣏ࢢ६Ѷ哦 ‫לޣ‬ԖЗ֡٠֪ո֡ଢ଼٠֪ࣩ֋ЎўҚ ‫ۊ‬њࣩ҄շ ո‫ޑہ‬ Ӫ‫ݰ‬哦ࢢ ‫޲ݰॺܮ‬ӱ澝‫ٴޱ۪ݰ‬ՕЉ۞‫ࣣ࣢ى‬ஔ‫־‬ Օિ‫ܛ‬ङӫ‫ޏ‬ қ‫ڱ‬Ғ૓ङսૅ ҵࣁԖ զ੐ࠆԖ澝֡ଢ଼ԖࣩbiopharmaऻҠՆ‫ى‬ © 2025 Henlius.

5. Slide 5: Biosimilar commercialization revenue

   ‫יޟ‬६Ѷ哦ॡ঎ਠԍ‫ڬ‬Նͧӹ‫ܗ‬ҵࣁ٠֪ • 2024‫ࢢ࣏ͧٵ‬६Ѷ哦㔀ଵֈ஛૖35.8ыъࠨٟ澞HLX11 (٦‫ࢿ׳‬Ԥ۱ͤ澝HLX14 (֩৭Ԥ۱) ૡҴІ٠࣓੻਑Ոࣂ୘ࠝͧդডॡ঎䃑ࣴCTLA-4澝CD38ॗҵࣁ䏣ୈ杴䎯ͧբࠖ‫טࡢىڏ‬К ‫ͧټ‬Н١‫ف‬ҵࣁ٠֪ۙЇֲ‫ׁؗ‬क • ࠯‫ޝ‬Ѩ®֧ষ֡澝ԅ‫לܔ‬਑‫ۦ‬І٠‫ۉ؎ٶ‬ந‫֋ۦ‬ЎԖՆઓ২ԗষͧНҷ՚நЖૹ૚FDA‫ۦ‬Ӕ֧ষ֡‫֋ىڏ‬ЎԖࣩуռ • ࠯Ӯ‫®ڈ‬ऱஸ਑‫ͧۦ‬Нҷ՚ॕЅࠏࡢ‫ט‬਑‫ۦ‬І٠১ऒуռͧԅૻ㖥Ղ‫ݰ‬Ҽ٠֪֡‫؞‬ • ࠯ઍࡋ®਑ࢼӮঢнAGEMED‫ۦ‬ӔІ٠ͧНҷ՚ॕ

6. Slide 6: HLX10 (PD-1) approvals

   Ӫ‫ݰ‬哦‫ݯ‬ஸӮԤ۱͵ࢋ֧բ६‫҃ޣ‬PD-1Ԥ۱ͧ恱Ҵ૵஼ҵࣁ٠֪‫ݰ‬୘ࠝ ҵࣁநЖ਑‫࣐ۦ‬и࠿࣠▁঎‫س‬঑劌剫䣪ࣩ۱PD-1Ԥ۱ HLX10 (PD-1) ‫ݯ‬ஸӮԤ۱ 2024‫ٵ‬ASCO‫ى‬ठ֡ଢ଼‫י‬З‫ڵ‬IIIޫASTRUM-005ऒा‫ى‬ठ‫ݰޣ‬୩੧ऒाগ߈ ࠯‫® ࢩݯ‬ | Zerpidio ® | Hetronifly ® 2022‫ٵ‬3‫ޤ‬ 2023‫ٵ‬12‫ޤ‬ 2025‫ٵ‬2‫ޤ‬ З֡਑‫ۦ‬ АԦн਑‫ۦ‬ ࠍࣸ਑‫ۦ‬ ‫ݕ‬௤Tূ劌ࡴ‫ۅ‬ ‫ݼڠ‬઩‫ح‬PD-1ӄթ ৈՠ੮ѹவ॥‫ם‬ ԩࡁଇ55% ‫ݕ‬௤Tূ劌ࡴ‫ۅ‬ ӗ

7. Slide 7: Overseas approvals and global commercialization progress

   ࠯望ҵࣁԖଂષІٜকՇ‫߈ۉי੼ڰ‬ ষ֡ ࠍࣸՂਅ֡ ‫ޯݺ‬ ࡎ޼ѩ®ੂ FDA‫܅‬ӕЇ١ͫ‫ۨ؏ٷ‬௙‫֌܅‬ЏԗՇૄ ࡎ‫ࠬ®ࣙގ‬नੂ‫ٷͫ܅‬଒ҵਸ਼֢ӫ‫ޏ‬કՕЊӕҵପଳ ࡎ‫৻®ࣙގ‬ՠાѦ࣯ԥ‫ܐ‬չԗऐ▲ি࡞ऐ૴१‫ۅ‬ৈफ剔䣫֢எ‫ך‬ И‫ڶ‬IIIߊЛ‫ूٽ‬९֨‫ߎޙۨ؏ٷ܅ੂߎޙ‬௙҆‫ے‬ৱো哦 HLX14(֪ਞԥ‫)ܐ‬, HLX11(٧‫࣯״‬ԥ‫)ܐ‬Ї١કՕःબੂFDAՉࣲ HLX14(֪ਞԥ‫ࠬ)ܐ‬नMAAੂՉࣲ HLX22 (HER2) ֢எ‫ך‬И‫ڶ‬IIIߊЛ‫ٽ‬ડ௠ੂ‫ۨٷيڐ܅‬ԅՓ‫ޙڐ‬ HLX15 (ଇப‫ػ״‬ԥ‫ )ܐ‬42

8. Slide 8: Commercialization

   02 ֋ЎԖ © 2025 Henlius.

9. Slide 9: Zercepac (HLX02) trastuzumab

   ࠯‫ޝ‬Ѩ®ͣ‫ࢿ׳ޝ‬Ԥ۱ͤ͵਑‫ۦ‬І٠֡‫؞‬ո֩ԙ‫ࣩ֡יޣ‬у࣏ࢢ६Ѷ哦 ֡ଢ଼ռઔ प‫ט‬㘦З 28.10ы* • ௙Зੂ‫܅‬Ї١ङ֢ф޼‫࣯״‬ԥ‫ܐ‬ • ਘ‫֌ڏ‬Џԗ֝஄П‫֨ح‬И֢‫׋‬ӄङ֌Џԗ‫ͫٺݐ‬ • ௙З֨ࠬࡳੂ‫܅‬Ї١ङ“И֢书”ԥ‫࣒ࣿܐ‬ঝѷ哦 ঳600դЋЏы‫ۨুב‬ङ֌Џԗ֝஄ͫৼࢾг 匝䣫࡞ऐ௅ֿͫҶவ੾तҶ֢ҹ‫ם‬୦։Ԛֿ 2024‫ݗٵ‬Ҵ • ֨২֢澝Ԇܳ‫܅ੂם‬Ї١ͫۨО֨И֢澝ࠬࡳ澝২֢ І֪֮ੂ‫܅‬ङ“И֢书”࣒ࣿঝѷ哦 • ਚԃйȔЉએ▲ЗHER2 ஆ‫ےۅ‬ৱ੊Јȕܴͫ ৒֠৉ԛ؆‫ݾ‬ਃ澝ԛऐ‫݇ރם‬澝HER2ࠒࡹ

10. Slide 10: HLX11 pertuzumab biosimilar

    ࠯‫ޝ‬Ѩ®ࢮ▁‫ݸ‬зࣩՄ੐ߡո֡ଢ଼ռઔ٪޼ਸ਼ЎஔҮࣩъ࣏֭уԂ Ѩи֡Ӄ Ӫ‫ݰ‬哦Ѣ ▁঎ъ࣏֭уԂ ࣩъ࣏֭ બ500Є уԂ 2024‫څٵ‬ ։▁Մ੐ߡࣩ‫ࢿ׳ޝ‬Ԥ۱ ‫ڟ‬ԖуռѨԍͧ‫ैڎ‬ोеѨԍ Ն‫ޝ࠯ܝ‬Ѩ®Љ࠯‫®҃ר‬ ࣩԢբҀ࣐ ٚ‫ڐ‬Ԗज़ • ‫ݽ‬୩֪Շ࣫١֫䡺ࢵͫОИ֢ • சवҿѕ޼‫࣯״‬ԥ‫ܐ‬фսͫљՃ޼‫࣯״‬ • ۨԅЇ١ࡎ‫߁ܞשͧ®҄ש‬ ࣛͧ‫تڀ‬ HER2+г匝䣫‫ے‬ৱ୏૯ؔӲͫ ‫ݐ‬ӟՅઁࠀӷֺ ԥ‫ܐ‬जЈӷֺչ٧‫࣯״޼࣯״‬जЈӷֺ হҵԛґͫॼж‫ہ‬Ԏ‫ޙ‬ञ‫ߒז‬ ‫ͫͨؿ‬Њࡎ޼ѩ®ԣգ‫ͫٺݐ‬ ‫ࡎؐזر‬

11. Slide 11: Hanshuyou neratinib

    ࠯‫͵ͤؾޢۿרͣ®҃ר‬уռԢբͧ⻒‫ؗ‬HER2+в匝䣪ॡ঎ 0.45ыҪ 2024‫ݗٵ‬ҴͣІ٠ଵֈ3Ж‫ͤޤי‬ уռԢբ • ‫(ؿ߁ܞש‬Neratinib)ީ▲य़Ս߆ङЉՕଢङࡤHER ‫֋ى܃‬ЎԖ١‫ف‬ • ҭӣӯऀࡎ޼ѩ֌Џԗ֝஄ٝ߄ङ١֫੾तਈԃљ 懗㾓懤ࢬ懢‫܌‬Ӳӷ(TKI)澞ࡎ‫ީ®҄ש‬Ҹ՛г匝䣫࡞ऐ Ճ‫ۯؚ‬૏࢛ͫ޾‫֪ڽ‬澝޾‫ݕ֪ࡤٺ‬ԟHER2ஆ‫ߊޝۅ‬ ௅ֿՁ▲࠮୍੽фսͫЊ঒িИ࣫߄фսࡎ޼ѩ‫ڥ‬ г匝䣫‫ڠ‬ԗૼԉ࡞ऐङऽެࣤչ࡞ऐࣤͫ‫ݐ‬Ԉ‫ڠ‬ԗ ۨԣգͫ߄߈଒▲࠵஑ѺHER2ஆ‫ߊޝۅ‬г匝䣫‫ے‬ৱ ૼԉऩ߶ы৩(‫ߊޝ‬HER2

12. Slide 12: HLX10 Hansizhuang

    ࠯‫ݯͣ®ࢩݯ‬ஸӮԤ۱ͤ͵૯‫ࣼࣤڀ‬ট਑‫ͧۦ‬ҵ஄੍ࣴ‫ޫޏ‬剫䣪ոடॡ䣪 ਑‫ࡅٹڰ‬ੜՔ ٚ‫ڐ‬Ԗज़ࣛͧ૙ૻ۴Ԩ٠֪ 13.13ы* • Ҷࣱ௙Зੂ‫▲܅‬ি࡞ऐES-SCLCङ‫ܐ‬PD-1ԥ‫ܐ‬ • ▲িள沨ࣙள‫ূش‬劌剫䣫ଠ‫ځ‬औй2024‫ٶ‬12߃֢֨ӄੂ ‫܅‬Ї١ • வ‫ث‬PD-(L)1١֫ࢬࢸङॼж࣪‫ͫ׋‬Ӳؔٛ‫ڑ‬ԗङੈ୦ ঌऋͫ⼂‫ূشؘ‬劌剫䣫௅ֿ剰䣃Ҳ䡏࡞ऐङ௅‫ح‬ৱ֪ ѹͫ‫ݕ‬ԟள‫ূش‬劌剫䣫չௐ঒䣫١֫ѡௌͫ‫ڠ‬ԗ‫ثۯؚ‬ 2024‫ݗٵ‬Ҵ фսङҒ‫ڶ‬ • 2025‫ٶ‬2߃ͫйࠬनੂ‫܅‬Ї١ͫऀй▲ি࡞ऐ‫شߊࡤٺ‬ ূ

13. Slide 13: HLX10 Phase III expansion

    ࠯‫®ࢩݯ‬Ӟ৸ࣩ֋ЎԖ‫ࢴݝ‬ոٚ‫ڐ‬Ԗуռज़ࣛ ▁ࡗࣩ֋ ▁঎ъ࣏֭уԂ ЎԖ‫ࢴݝ‬ બ240Є 13.13ыҪ 2024‫څٵ‬ 2024‫څٵ‬ ٚ‫ڐ‬Ԗज़ࣛͧ ҵ஄‫ڏ‬Ն ܶԞடॡ沨䣪 ܶӸ١‫ف‬ োࢎ‫س‬঑劌剫䣪 ஂ‫س‬঑劌剫䣪٠֪ ٠֪Ѡ஛ গࣻ剔䣪ո剳䣪 ٚ‫ڐ‬Ԗज़ ͣԨ㔀Ѽ剫䣪㕨ীࣩ15-20%ͤ • ள沨ࣙள‫ূش‬劌剫䣫 • ‫ם‬ԃ‫֨®ࣙގࡎٺݐ‬ௐ • ‫ݕ‬ӹ٢‫ͫق‬Оߌߛङ ࣛͧ‫تڀ‬ • ॥ߢ‫ॼثځ‬ս֨‫ূش‬劌 剫䣫௅ֿ٫ߛङܸ۫ͫ ଠ‫ځ‬औङੂ‫ءܢͫ܅‬ ঒䣫Ҳ䡏࡞ऐѩԎы৩ ৈफ剔䣫չ剳䣫௅ֿ дࡎ‫֨ࣙގ‬剫䣫௅ֿ ИङԤ૞

14. Slide 14: HLX04 bevacizumab

    ࠯ઍࡋ®ͣઍѥࢿԤ۱ͤ͵Մૹଂ٠֪Ґ‫ܕ‬ளૻ‫׌‬େ ऴ߃‫֋ى܃‬ЎԖ١‫ف‬ ࣐哦‫ॺܮݰ‬ 1.97ы 2024‫ݗٵ‬Ҵ ֡Ӄ٠֪ • ؏ۨ31मԛґ੊֪ͫ28म‫ܵ߶ܥ‬ৠ • И֢֊▲‫૴߄ܨ‬१‫ۅ‬ৈफ剔䣫IIIߊЛ‫݇ރٽ‬ङ ાѦ࣯ԥ‫ܐ‬ • ৼࢾՅପଳ١֫ͫ‫ݕ‬ԟ١֫‫ג‬஺ͫ‫ڽ‬ବ‫׍‬Ԇ୦୏ • Օ৻ՠࡎ‫ܐͧ®ࣙގ‬PD-1ԥ‫يڐͨܐ‬剰䣃Ҳ䡏 բࠢ‫׌‬େ65% • ॥ߢ‫ࡌج‬ளՅପଳ֪Ԛङԛஓӕҵߑѫ ৻ՠऐࡣͫ‫ऀࡤٺ‬й՟ঝ剰䣃࡞ऐ • ॥ߢՀЊम঴த୊жՈߑѫ ֡ଢ଼٠֪ • Њ Eurofarma ՠҁͫ݉еҿ֨‫੼׎‬ւ澝஋߿‫ڎ‬澝 ޴ӯঈ

15. Slide 15: HLX01 and HLX03

    ࠯Ӯ‫ͣ®ڈ‬Ӯ‫׳‬㨓Ԥ۱ͤ͵㌓֠٠֪ஔ‫֩ج‬Ѹ ࠯૖ૢ®ͣ୚૖ެԤ۱ͤ͵١‫ف‬১ાұ䡎࣢ࣣஔ‫־‬ 5.28ы 2024‫࠯؏וٵ‬望 ۶਽ॏ‫ݗ‬Ҵ 0.40ыҪ 2024‫࠯؏וٵ‬望 ۶਽ॏ‫ݗ‬Ҵ ֡ӃநЖ࣏ࢢ६Ѷ哦 ਫ਼ࠠ▁Ж㕨ী‫࠿ؿ࠿ڀ‬ • 2019.02ੂ‫ͫ܅‬И֢௙З࣒ࣿঝѷ哦ͫ௙З֢фӯ‫״‬㨥ԥ‫ܐ‬ • Ҹ՛௙࠮࡞ऐਘ૯Ҳ䡏ऒओङфս • 2022.02‫ޏ‬ଠ‫ځ‬औੂ‫ͫ܅‬И֢௙Зੂ‫܅‬ঝ௎࢘Ҽਭ䎏ͧRAͨङӯ‫״‬㨥ԥ‫ܐ‬ • ֢ӄ௙З୓‫ث‬И֢ୣㆼओ‫ے‬ৱ‫يڐ‬IIIߊЛ‫ूٽ‬९ङ஋ଇߋԥ‫࣒ࣿܐ‬ঝѷ哦 • ۨॹ֢ӄ௙З୓‫ث‬ਘ૯Ҳ䡏

16. Slide 16: Business development

    03 ֋Ԇ‫ى܃‬ © 2025 Henlius.

17. Slide 17: Abbott and Dr. Reddy's licensing deals

    ૝ޫ֋Ԇ‫ى܃‬һି‫޴ܪטت‬уռ Abbott Products Dr. Reddy’s Operations AG. Laboratories SA ՟բढ़ਜ਼‫ޫݺ‬: 2024/12/31 ՟բढ़ਜ਼‫ޫݺ‬: 2025/02/06 ‫ى܃‬՟Ҁуռո֩ԙ ‫޴ܪטت‬ ֙ࠏଜञ࣏ࢢ६Ѷ哦ո▁ࠏ࣏ࢢӪ‫ݰ‬哦 HLX15 (૖୹‫غ׳‬Ԥ۱࣏ࢢ६Ѷ哦) 69Ж‫ݰ‬Ҽ٠֪֡‫੍ࣴͣ؞‬нࡔ澝‫▂ۿ‬ষ ষ֡Ղ42Жࠍࡔ֡‫؞‬ո֩ԙ ࡔոԅԎࠢࡢ֩ԙՂЗАԗஂͤ 3300ЄষҪநѕࠏ澝㔀ଟ஛બ1.3ыষҪ ंԽԥ▲֢‫؟‬ՠҁ‫ي۽‬ਙ޾‫ޏך‬ҽ١֫ͫ૏࢛‫ޅ‬ՠ Ҷࣱघь١қ୍ॎфս

18. Slide 18: Breast cancer BD strategy

    ‫ڕטت‬ૡোࢎ͵ૹ૚BD‫ڕ‬ૡ‫تى܃‬в匝䣪Јբнֹࣩ١‫ف‬ ER+/ ६ֹ в匝䣪ஔ‫־‬уռ HER2+ HER2- ‫ॺۿ‬㨓৽ (‫س‬Ӣ‫׾‬SERM*): • ‫ܞ‬ফ㨥ਮ‫ث‬஦ࢬপՉѽͧERͨङ࣒ࣿࡴ‫ۅ‬Ӏ߄ুৃ ଣ‫ۅܫ‬ͺER֨г匝䣫औূ劌И੮࣫ӟ‫܌‬Ӳࡴ‫ͫۅ‬գ ‫ޞ‬Օљࢬࡴ௣ুৃূ劌 ‫ؾޢۿר‬ (࠯‫)®҃ר‬ • ‫ܞ‬ফ㨥ਮӀ߄ߛਘESR1ॳՊ䣫औङДЗIIߊЛ‫ٽ‬ડ ֟‫ޫޱ‬ ௠ङஆ‫݇ރۅ‬ͺЊ஋ા੼ӯͧ䮠ߛCDK4/6‫܌‬Ӳӷͨ ৻ՠ҅ऀͫ‫ޗ‬଒‫ͧߊ؂ࣿي‬PFSͨଇӱ13.9З߃ͫ㾋 ৓՛৩৻ՠ஋ા੼ӯङԷ՗PFSО5З߃٘՘

19. Slide 19: Global commercialization partners

    ‫޴ܪטت‬োࢎ͵‫࠯؏ו‬望֡ଢ଼ռઔࣩ࣏ࢢ६Ѷ哦ଵ‫ک‬ҵࣁ٠֪ Լऒ哦Ղ࣏ࢢ६Ѷ哦٠֪੐ࠆ ٜ‫޴ܪטتޥ‬՟Ҁѩѳ ‫ࠍݸظ‬ষ‫޴ܪ‬՟Ҁѩѳ 2024‫ٶ‬Ҷࣱ୦։ௌͧь২ҫͨ 2024‫ٶ‬Ҷࣱ୦։ௌͧь২ҫͨ HLX17- ࠍࣸ澝ষ֡澝ԅ‫לܔ‬澝Аࣸ澝 HLX03- ٦ԧӮࢿԤ۱ ЗАոԗஂॗ֩ԙ՟Ҁѩѳ PD-1 ୚૖ެԤ۱ 294.8 Abbott TNF-Į (362.6)* 161.5 HLX18- ঈࠗӮ‫غ‬Ԥ۱ HLX02- HLX15- PD-1 Аࣸ澝ЗАոԗஂॗ֩ԙ՟Ҁѩѳ 102.0 HLX16- ‫ࢿ׳ޝ‬Ԥ۱ ૖୹‫غ׳‬Ԥ۱ HLX1102- HER

20. Slide 20: R&D

    04 ऒՆ © 2025 Henlius.

21. Slide 21: Pipeline and clinical stages

    уռঐ՟ոॡ঎ Pre-IND / IND Iޫ IIޫ IIIޫ NDA І٠ (6) (1ͨ HLX6018 HLX10(5)ͧ‫ގ‬௩ӯԥ‫ͨܐ‬+ HLX07 HLX10(5)ͧ‫ގ‬௩ӯԥ‫ͨܐ‬+ ԗऐ HLX14֪ͧਞԥ‫( ͨܐ‬12) ࡎ‫ގͧ ®ࣙގ‬௩ӯԥ‫(ͨܐ‬5) HLX79 GARP/TGF-ȕ PD-1+EGFR PD-1 RANKL PD-1 ы⭧䃠懤懢壝ՠ堢ग ࣔՇ‫ۅ‬剫ল৓ԗ ‫ף‬ேୂ沨ࣙূ劌䣫ͫ௶ռ䣫ͫ沨ࣙள‫ূش‬ ‫ূشߊࡤٺ‬劌剫䣫 1L ௣ૅऎߠऔঈ 沨ࣙள‫ূش‬劌剫䣫ͫ‫ূشߊࡤٺ‬劌剫䣫ͫ ࡴԈߊ副‫ࣱش‬副䎏 劌剫䣫ঈ‫ؘ‬ѽ䣃 ௐ঒

22. Slide 22: 2024 R&D milestones

    К‫ټ‬ॡ঎һିૡस͵2024‫֚ٵ‬ஐ 2024 HLX04࠯ઍࡋ® HLX01࠯Ӯ‫®ڈ‬ HLX10࠯‫®ࢩݯ‬ HLX10࠯‫®ࢩݯ‬ HLX14 ૴१‫ۅ‬ৈफ剔䣫ͫޮߊ澝 HLX11 ளம‫୐ר‬䃷ٞ䣃ۣͫ‫ۅ‬ ‫ূشߊࡤٺ‬劌剫䣫 沨ࣙள‫ূش‬劌剫䣫 ্৆ե௣ૅऎߠঈ ૴१‫ז۪ۅ‬Շ‫ۅ‬ள‫ূش‬劌 г匝䣫 䃷ٞূ劌ग੦ओͫঝ௎ ▲ি࡞ऐͧ੅‫آگ‬澝ਸ਼֢澝 ▲ি࡞ऐͧԭ‫ؿ‬澝ࡪ֢澝 剫䣫ͫਇૅ࠾ূ劌䣃ঈ ‫ૼޏ‬ԉ࡞ऐͧИ֢&২֢ͨ ͧࠬन&Ԇܳ‫&ם‬২֢ͨ ࢘Ҽਭ䎏 (‫ܞ‬২֢‫)؟‬ ࣶ‫ב‬澝૞ԧ澝ԭ‫ͨچ‬ ߳‫ͨة־‬ ͧХ‫ͨ֩ܞ‬ ܶрNDA/BLA

23. Slide 23: 2025 milestones

    К‫ټ‬ॡ঎һିૡस͵2025 2025H1 2025H2 HLX10࠯‫®ࢩݯ‬ HLX10࠯‫®ࢩݯ‬ HLX10࠯‫®ࢩݯ‬ HLX04࠯ઍࡋ® HLX04-O HLX14 HLX10࠯‫®ࢩݯ‬ ‫ূشߊࡤٺ‬劌剫䣫 沨ࣙள‫ূش‬劌剫䣫 ள沨ࣙள‫ূش‬劌剫 ૴१‫ۅ‬ৈफ剔䣫ͫޮߊ澝૴ ࢘‫ٶۅ‬௹बҼ‫ۅ‬௰‫އ‬Պ‫ۅ‬ ্৆ե௣ૅऎߠঈ ௐ঒沨ࣙূ劌䣫 ▲ি࡞ऐͧИ֢௚࢔澝 ▲ি࡞ऐͧ੅‫ ͨآگ‬䣫 १‫ז۪ۅ‬Շ‫ۅ‬ள‫ূش‬劌剫 ▲ি࡞ऐ ͧਸ਼֢ ͨ ▲ি࡞ऐͧࠬनͨ ИБљՃԘள֢‫؟‬澝֦ ▲ি࡞ऐͧԭ‫ؿ‬澝 䣫ͫਇૅ࠾ূ劌䣃ঈ ͧ২֢ͨ ৶ҿ澝‫ܞ‬২֢‫ͨ؟

24. Slide 24: HLX10-015-CRC301 clinical results

    HLX10-015-CRC301К‫ੰټ‬யগ߈ ‫۬݇ރ‬ਙ͹2024/6/30ͺИѹசઘ‫୸ޞ‬͹31.0З߃ • ࠯‫ݯͣ®ࢩݯ‬ஸӮԤ۱ͤ৊՟࠯ઍࡋ®ͣHLX04ͧઍѥࢿԤ۱ͤոԖ࣐࣠и▁঎࠿࣠ૃश㓬গࣻ剔䣪ͣmCRCࣩͤIIIޫК‫ټ‬ऒाͣHLX10-015-CRC301ͤগ߈ј‫׏‬۶‫ړڤ‬Ҵ૲2025‫ٵ‬ ষ֡К‫ټ‬剰䣂؅Ѫ剳剔ଂ剰䣂ऒ੝ѪͣASCO GIͤ • ੴऒाগ߈‫ދ‬ठ֧ͧૃश㓬গࣻ剔䣪㕨ীЗͧЉ،㘯ӶԅઍѥࢿԤ۱ոԖ࣠ࣼࠢͧ‫ݯ‬ஸӮԤ۱৊՟ઍѥࢿԤ۱ոԖ࣠‫ދ‬ਚ‫ޭ֐ݘ‬ক࠿ࣩ࣠mCRC㕨ী࣏‫ͧޫ؁‬Ћ،ҵ㓬Քܰ澞ГЖ࠿࣠ ঐӞࢻʅ3ঃ࠿࣠ࣼһЈ৶жѝ

25. Slide 25: HLX10 gastric cancer neoadjuvant

    ‫ݯ‬ஸӮԤ۱͵١‫ف‬ٚ‫ڐ‬Ԗ૯‫ࣤڀ‬ ݇Checkmate 649ડ௠Չડৱׂি‫݇ރ‬ӣߤͫ60%ޮߊ剳䣫‫ے‬ৱCPS•5澞 ߎડ௠ગઋѤ‫׷‬ԯ‫ݕ‬ӹ୧ؔPD-L1ஆ‫ͧۅ‬CPS•5ͨы৩ͫ҅‫ގ‬௩ӯԥ‫ۨ߈߄ܐ‬ОҵࣁஔҮ澝 ֡Ӄ։▁剳䣪֟‫ޫޱ‬ұ䡎哦ࢢ 剳䣪 ۩֢࠿‫ޏٶ‬Շ剳䣫঳40Ѕ҆1,2ͫҿИ঳2/3‫ے‬ৱଠ‫ؖ‬଒੧֠۴ߐߊ࡞ऐ2ͫசव剳୶ࠒ߲ޯ Ճͫથୂӣ‫ے‬ৱ‫ر‬ଦ‫ٶ‬ଧ‫׍‬ ‫ݰ‬ોԈ৊՟Ԗ࣠/ોԈ‫ݯ‬ஸӮԤ哦 ऩӹ剳䣫֠ߐߊ߶ӕ࡞ऐИѹ‫ޗ‬зўࣿ‫ߊ؂‬঳3‫ײͫٶ‬ડ௠ۨԅͫ௄ઋ‫ୂם‬ӣ‫ے‬ৱ҅ऀ‫ގ‬ ௩ӯԥ‫ر୿ޞܐ‬Օଇ20

26. Slide 26: HLX22 HER2 gastric cancer first-line

    HLX22͵ҿ‫ݘޥ‬ՉࣹӸ▁঎剳䣪SOCࣩࢋԂ HLX22ͣHER2ͤ • HLX22杴էHer2ङdomain IVङЈբ੮ѹ澞ЊգО杴էHer2 domain IVङ޼‫࣯״‬ԥ‫ܐ‬ङ৻ՠͫՕգ‫ޞ‬ҏ଒ HER2/HER2 գ࢛и ৼѽչ HER2/EGFR ‫࢛ڑ‬иৼѽङӄթҁऀͫ‫ر‬HER2ङӄթ‫ݕ‬௤ 40-80%ͫ PDx‫ު݇ރ‬ॐͫ޼‫࣯״‬ԥ‫ܐ‬ЊHLX22ङ৻ऀऐࡣ֨剳䣫 ଠ‫ځ‬औЇࡁ޼‫࣯״‬ԥ‫৻ܐ‬ՠ٧‫࣯״‬ԥ‫޾ܐ‬ӀѩԎ • ׂй࣫உ࠼Л‫ٽ‬IIߊ‫૴֨ͫ݇ރ‬१‫ۅ‬剳䣫չ剳ௐ঒сउ䣫ङ▲ি࡞ऐ ИЊ࣫੧߶ӕ࡞ऐͧ2010‫܅ੂٶ‬ङ޼‫࣯״

27. Slide 27: HLX22-GC-201 clinical results

    HLX22-GC-201К‫ੰټ‬யগ߈ ‫۬݇ރ‬ਙ͹2024/6/30ͺИѹசઘ‫୸ޞ‬͹HLX22ু20.3З߃ͫ‫؍‬㙁ӷু24.0З߃ • Ӫ‫ֹݰ‬۱HER2Ԥ۱HLX22৊՟࠯‫ޝ‬Ѩ®ͣHLX02ͧ‫ࢿ׳ޝ‬Ԥ۱ͤոԖ࣐࣠и▁঎࠿࣠HER2୕㓬‫ف‬଑‫ૃۋޫޏ‬श㓬剳/剳டॡрࣙ଑ͣG/GEJͤ䣪ࣩIIޫК‫ټ‬ऒाͣHLX22-GC-201ͤগ߈ј ‫׏‬۶‫ړڤ‬Ҵ૲2025‫ٵ‬ষ֡К‫ټ‬剰䣂؅Ѫ剳剔ଂ剰䣂ऒ੝ѪͣASCO GIͤ • ऒाগ߈‫ދ‬ठ֧ͧHLX02+XELOXׁࣩकІԅҴHLX22ՔܶளHER2୕㓬G/GEJ䣪㕨ী▁঎࠿ࣩ࣏࣠‫ޫ؁‬ո۱剰䣂Յ‫ͧڀ

28. Slide 28: HLX22-GC-201 PFS and OS data

    HLX22-GC-201Оੌऒाও䎯͵‫ݸ‬ૡ‫ޫ؁࣏ى‬јՂ㔀࣏‫ޫ؁‬ ंࣞॹ‫ڧ‬Ҧછѳ‫׹‬մѫ߿݇‫ؘ‬ѽ 䣃ր‫ځ‬છѳ߶ӕ1.1࣍છѳ • ‫ۍ‬২2024‫ٵ‬06‫ޤ‬30‫ͧݺ‬ҾЗHLX22ঐЗѸ୩੧‫ ୎ݿ‬20.3Ж‫ ͧޤ‬،㘯Ӷঐ24Ж‫ޤ‬ HLX22 + ‫ࢿ׳ޝ‬Ԥ۱ + XELOX ،㘯Ӷ + ‫ࢿ׳ޝ‬Ԥ۱ + XELOX HLX22 ঐ ،㘯Ӷঐ (n = 31) (n = 31) mPFS, months (95% CI) NR (23.5–NE) 8.3 (5.7–12.7) HR (95% CI) 0.2 (0.06–0.45) p<0.0001

29. Slide 29: HLX43 PD-L1 ADC

    HLX43͵TMALIN*૤‫׾ܯ‬ոTOPO1iࠡॹૉ਍ࣩ۱PD-L1 ADCͧ Ї▁іI/O ADCઞу ۱PD-L1۱Ѽ һି‫ي‬㓬 ‫ڏ‬Նज़ࣛ • ௤ৈՠਈԃչՕӄԗङы࢛ԗIgG1ͫЛ‫ूٽ‬९ٝ • PD-L1ͫ‫ࡤٺ‬ङ剰䣃И௤੮ଇͫ৲֨࠳‫ৃুٯ‬ИѺ ௠ચ‫؍‬Ҷ‫ͫۅ‬Ӏ߄IP ੮ଇͫ▲Зॼжࠀ‫ױق‬Ќ‫ࡤٺऀځ‬ङADC杴ࢵ • Օ੷આЌ剰䣂‫ͣ׊ࢺڲ‬TMEͤࢍࡕङІ剮କ‫׿ݎ‬ • ‫৻ؖ‬TMALINକ‫ࣔࣞ׿ݎ‬ङࡀপୋ‫ߑݹ‬Ӳ • ‫࣪ڲ‬੦䃠И௤‫چ‬६ؔङକ‫׿ݎ‬ • ௤‫ݼ‬ਈङ‫߄ڐۘ܃‬懢1ۭӱӶૺਾͫӀ߄िԡੰߊչ • ௤‫ݼ‬չѺԡੰߊङ

30. Slide 30: HLX43 PD-L1 expression and patient populations

    HLX43: ֧‫י‬म६ֹࣩ‫ؗ‬Ѽ䣂IIޫК‫ټ‬Зૡਸ਼࣠‫ॺܮݝ‬ ֧‫י‬म‫ؗ‬Ѽ䣂З‫ࡅٹ‬਽૖ ࠳‫ৃুٯ‬੮ଇࡊ‫ٵ‬Ѻ | П੽‫ق‬ஒйҲ䡏ূ劌 ࡗਸ਼ࣣ؅ ‫ؗ‬Ѽ䣂 PDL1 ਽૖ ࡗਸ਼ࣣ؅ ऩ߶ଠ‫ځ‬औ ऩ߶ଠ‫ځ‬औ ‫چٶ‬зў‫ރ‬ ‫چٶ‬зў‫ރ‬ З֡/ҵࣁ HLX43 HLX43 З֡/ҵࣁ TPS ͽ1% | •50% CPS >1% 剫䣪 (NSCLC) 剳䣪 1000k/2000k ¥ 71% | 37% 84% ¥ 470k/1140k গ剔䣪 டॡ䣪 510k/1900k ¥ 31% | 5% 86% ¥ 320k/600k ԰㌐䣪 剑঑劌䣪

31. Slide 31: HLX43 preclinical and early clinical data

    HLX43͵‫ࢻى‬Ѩ‫ڐ‬К‫ټ‬Ӹ哦‫ٶܨݤݝ‬ٜૡҴК‫ټ‬IIޫ К‫ټ‬Ӹ‫ؗ‬யগ߈ • HLX43‫ت‬PD-L1୕㓬ъ६۱Լձ૶঑劌‫ݸ‬ұ䡎ࠡ㓬 HLX43‫ت‬PD-L1୕㓬ъ६۱Լձ૶঑劌‫ݸ‬ұ䡎ࠡ㓬 HLX43‫ࢻى‬Ѩ‫ݳࣩڐ‬੏ী‫ڀݝ‬ • HLX43‫ࢻى‬Ѩ‫ݳࣩڐ‬੏ী‫ڀݝ‬ • ֧ѼӃ哦‫ݝ‬ऒाЗͧHLX43֧‫י‬मPD-L1+CDXոPDXࠆֹЗ੸‫ج‬剰䣂ࡤ૭ͧ ‫ٶ‬Ћ哦ࢢ،ҵ㓬৶‫ͧװ‬Љ‫࢑ت‬ঐࣼࠢ՞Ӷଞঐচ哦‫س‬௄Ѽଜ֭‫ދރݸ‬ՉԖ I. ֨MDA-MB-231ֺࠥИͫ࠿յো哦▲ࠩͫ૤ড࠿࣠Ѕմդԇࢢࣩ剰䣂Ѽऴ ‫ދ‬ਚব‫ͧس‬

32. Slide 32: HLX43 efficacy in PDX and CDX models

    HLX43֧ЈբPDXЉCDXࠆֹЗࣩ۱剰䣂Ԅ‫ݝ‬ GC (treatment naïve, KRASm) 1 LU6437 PDX model 2 CRC (MSI-H, Pembro resistant) 3 PD-L1 IHC 3+, TPS 80% PD-L1 IHC 2+, TPS 70% (sqNSCLC PD-L1 IHC 2+, HLX10 resistant) Model with hPBMC reconstitution Vehicle control C24,0.24 mpk; TGI 34.12%(D21) 2000 HLX20, 10 mpk; TGI 14.89(

33. Slide 33: Innovation

    4.1 ‫ݾ‬ऒ © 2025 Henlius.

34. Slide 34: Innovation platforms

    ҿ‫ޥ‬ҵࣁोеԂࣩٚ‫ڐ‬ԖӪ‫ݰ‬ऒՆ‫ٴ‬Օ Tri-specific TCE Platform HanjugatorTM ADC Platform HAI Club Anti- TAA Activation Signaling 2 of T cells Activation Anti- Signaling 1 TAA of T cells • ܴСङࣔ‫ڑ‬ङTূ劌ࢬࡴ‫ځݼ‬ • ‫࡞ם۽‬ऐॶՍ • ‫ޏ܇ج‬ङ哦࣒杴ࢵ • ѺҲ䡏ূ劌䂫䃔ङ剰䣃‫ي׋࣪ڳ‬ॐ޾‫ױ‬ङ哦‫ݼ‬ • ұ߆‫ऀ҅ࡤٺث‬ङࡀপङ৳哦‫ۅ‬ • ஑Ѻۨߎ‫ݕ‬௤‫ݼ‬ञङूՇ • ஑ѺCRSङՇࣿ •

35. Slide 35: Tri-specific TCE platform

    ‫ޟ‬،ҵ‫ࣩݝޥ‬TCEЅࢤ‫ڐ‬㓬‫ٴ‬Օ ѹT঑劌䂙䃂Ї‫ޟ‬Ѩࣩ哦‫ݝ‬ 1 TAA-dependent T cell Activation 3 Redirected Tumor Lysis ‫ޟ‬ѹࣩ঑劌֛‫׾‬ଚ‫ݚ‬ IL-6 IL-4 IL-10 5 1.0 150 4 0.8 IL-10 (pg/mL) IL-6 (pg/mL) 100 IL-4 (pg/mL) 3 0.6 2 0.4 2 CD3-dependent CD28 Activation 50 1 0.2 0 0.0 0 TAA: Tumor associated antigen 6h after first do

36. Slide 36: HLX97 KAT6A/B degrader

    HLX97: ࢋ֧ “ Best-In-Class” ࣩ࠿࣠ERŗ+в匝䣪ࣩՌާ‫س‬Ӣ‫ۭ׾‬ӱӶ Ռާ‫س‬Ӣ‫ۭ׾‬ӱӶ • ‫ޏ‬ҽङ੮઀଴Ѯ杴ࢵKAT6A/B • ߄Ӭ࠵Л‫ھࠢٽ‬௠ચङ杴ࢵ • Ҷ‫ޏ‬ҁऀߑӲͫ‫ך‬य़৻ऀՕਈ‫ٷ‬ұ߆৳哦 • Ӏ‫ו‬էӹি࡞ऐ㞱଒ङࢪԃ • ࡁॼս޾‫ڠ‬ङѽӄ‫ܐי‬剰䣃ࡴ‫ۅ‬ • ࣞࣔङPKࣔ‫ͫګ‬஑Ѻ哦࣒ङ‫޺࣪ڲ‬ர • ѩ‫ڑ‬ङADMET‫ૅۅ‬ • ߄߈આӐॼսङҼ୰Љૡ͹֨杴ङ੦बࡀ‫ۅ‬ 36 © 2025 Henlius.

37. Slide 37: HLX316 B7H3 sialidase

    HLX316: ▁ЖӪ‫ݰ‬ЋநӪB7H3杴䎯⬷䃎懤懢࠿࣠‫ؗ‬Ѽ䣂ࣩԄৗ㓬哦ࢢ 杴զԄৗӢ‫׾‬ Sialidase • B7H3 (CD276): ▲З‫ޏ‬ҽङऀй䣫औ࡞ऐङ‫ܐ‬Խ (TAA) Anti-B7H3 • Hypersialylation௤⭧䃠懤ԗ͹֨剰䣃ূ劌ଋ‫چ‬੮ଇ VHH ‫܌ٷ‬Ӳ剰䣃Ҳ䡏Ն‫ځ‬ • HLX316: Fc壝ՠङB7H3杴է⭧䃠懤懢ͫ‫ث‬剰䣃ূ劌 Ծ⭧䃠懤ђ৲‫ڠ׍‬Ҳ䡏Ն‫ځ‬ Fc • Palleon EAGLE‫ٵ‬Ֆङ⭧䃠懤懢 • HenliusՇ‫ޢ‬ङ‫ܐ‬B7H3 VHH • ӫ‫ޏ‬Ќ௙ӫ(FIC) 37 © 2025 Henli

38. Slide 38: HLX48 EGFR x c-MET ADC

    HLX48: ࢋ֧ “ Best-In-Class” ࣩ࠿࣠NSCLCոCRCࣩEGFR x c-MET ADC BISPECIFIC ANTIBODY • ஑ѺEGFRъչԃͫӗ‫ূٯ࠳ص‬劌ࡀ‫ۅ‬ Anti-c-MET Anti-EGFR • ‫ڠ׍‬c-METԥਖъչԃͫ‫ؘ࣫‬c-METѐ‫ح‬ ङ杴է‫ۅ‬ • ‫ܐڠ׍‬ѽӄթҁऀ • ґܴ‫ܐ‬ѽਖङ剰䣃‫܌‬Ӳࡴ‫ۅ‬ LINKER PAYLOAD • ௤६ؔङକ‫׿ݎ‬ • ѩԗङՠଠpotencyङpayload • ‫ם׍‬ङЛ‫࡞ٽ‬ऐॶՍ 38 © 2025 Henlius.

39. Slide 39: Operations

    05 ࣏у © 2025 Henlius.

40. Slide 40: Manufacturing capacity and GMP

    ֡ଢ଼ஔҮࣩ࣏уઔଞৗԂԈԂҵࣁ֋ЎԖ١‫ف‬ ‫ׂ֪ࡍڰ‬ ߠ㿄ׂ֪ ߠ㿄ׂ֪ ͧ▲ͨ ͧиͨ • уৗ‫ܕ‬ডѨԖ • ֡ଢ଼ߗӔઔଞѼॸ ֌ЏԗGMPࣿф‫ࠩ܅‬બ1000‫ۦ‬ • ஍ࣹ▁ޫԮ‫ؑݗࢁ֣ذ‬ (YS+SJ1) ࣏у‫ۉ‬Ԅࢴબ98% ੂ‫ڱ‬З֡澝ࠍࣸ澝ষ֡GMPੜ੩ ٝ؏ۨ▲ߊாऩ‫ޅ‬ѽԴ۰‫ڏ‬ગͫфਈ੾त • HLX02ͣ࠯‫ޝ‬Ѩ®ͤҵ஄‫ܕݖ‬ষ֡٠֪҇‫ڀ‬ Լ䃎澝ࠫଢӱӶ澝ஓҬଢՂADCҡ৊ࣿф • ј֡ଢ଼Ԗռઔહਸ਼Ȑ࠯望ઔଞȑ фս҈‫੾ځ‬तЗ֡澝ࠍࣸ澝ٝੋ澝Ԭ‫ؾڅ‬ • ԅૻܱૡ‫ݰ‬уռІ٠ • ‫ܱૻڼ‬ૡу঎‫ࢻؗ‬ҵࣁԖ҇‫ڀ‬ ੋн澝࠺ࢤ澝

41. Slide 41: AI and digital manufacturing

    ԣભ૜ਗͧ‫ܕ‬ডӪ‫ͧݰ‬㌓֠ਸ਼Ўஔ‫ج‬ী֩Ѹ ۪‫ޱ‬Ӫ‫ݰ‬ ॳ࣮૜ਗ AIટৗ ॳ࣮஍ࣹै஍બ200Ж ࣿфٗਫՃИ‫݇ރݏ‬ਘԈ‫܍‬ՈՃ૟Ԏ ॳ࣮૜ਗ ࡹ঑‫ٶ‬ԗ‫ݶ‬ञ૝ІԞЅ* ௄ࡹ঩৏؏ۨ‫ڐ‬Շࡹડ HLX01ͧࡎӯ‫ͨ®ډ‬ՃHLX04 ͧࡎાࡪ® ͨପଋٗਫѩԗͫૻ ிӯ؏ۨ‫޿ܞ‬Ұ崭 2023‫ܶٶ‬Ԟуଞબ10% ֨200LՆ‫֘ځ‬ЇङਘԈՆ௘‫ݏ‬Ӳࡹડ ۪‫ޱ‬Ӫ‫ݰ‬ ॸঞ‫ٴ‬Օ‫ڎ‬੦ ԣભ҇‫ڀ‬଴ ԣભ҇‫ڀ‬଴ BIॸঞ‫࣐ڀ‬ ࣒‫މ‬୊૆फ‫ݎ‬஑ߎ ࣿф澝ૅ୏澝҈‫ځ‬୥Ҽ୰ܶ‫ޞؘރ‬डࡹ 2024 ҵ‫ٵ‬ୠޯࠢ҅બ10%* ௎க௄

42. Slide 42: 2024 financial overview

    06 2024‫څٵ‬એԆ֚ஐ © 2025 Henlius.

43. Slide 43: Revenue by product

    2024‫ٵ‬ҵ‫ݗٵ‬Ҵং57.2ыҪͧբࠢ‫׌‬େ6.1% 㔀‫ݗ‬Ҵ(ъࠨٟы) уռ‫ݗ‬Ҵ(ъࠨٟы) 2024‫ݗٵ‬Ҵ߄‫(ۉ‬ъࠨٟы) 2024 2023 % ՟фս2024‫ݶ‬ҵԩࡁ 8.3% 6.1% 70.2% 49.1% 67.8% 49.3 28.1 27.4 57.2 45.5 53.9 22.9% 32.1 26.8 13.1 11.2 13.8% 9.2% 7.9 8.4 5.3 5.2 3.4% 0.7% 0.8% 2.0 1.2 0.4 0.6 0.5 0.0 ࡎӯ‫®ډ‬ ࡎ޼ѩ® ࡎଇଓ® ࡎ‫®ࣙގ‬ ࡎાࡪ® ࡎ‫®҄ש‬ BDՃ (ӯ‫״‬㨥ԥ

44. Slide 44: Profit, R&D expenses and cash

    2024ҵ‫ܕٵ‬ড䥞Ӯͧকਗ㓬ࢻଟӓࡗҴ12.4ыҪ ӓӮ䃂(ӓ◚‫͵)ܤ‬Ґ‫ܕ‬䥞Ӯ(ъࠨٟы) ऒՆࣼһ‫ݖ‬Ӟ(ъࠨٟы) Ӕӯ䃔(Ӕ☊݃)ࣤ Ӕӯ䃔(Ӕ☊݃) ‫߆҈ݕ‬ԇۨߎ* ૏ߎԗूՇ‫ݵ‬ӟ ોऀԗूՇ‫ݵ‬ӟ 14.3% 25.2 24.8 10.1% 3.4 21.1 6.4 8.20 7.9 6.8 5.46 8.1 3.1 (6.95) 13.9 11.2 10.4 -21.6% 2022 2023 2024 2022 2023 2024 *߿݇ѫઋ‫ؘ‬ԇͫЊ‫ߓ݉יث‬ङфս߄ҼङूՇ܎ҵઋҵ‫߆҈ݕ‬ԇۨߎ কਗ㓬ࢻଟࡗ‫ܕ‬ডНࠔ(ъࠨٟы) ՞஍ચ࣐Ԩ㔀‫

45. Slide 45: Financial summary YOY

    એԆ‫ੌ݅ܨݤ‬ ଑ӢએԆ‫ܨݤ‬ 2024 2023 YOY‫׌‬େ ԥѹ ыࡇ٠घЅҫ ԩ‫ݶ‬ҵ% ыࡇ٠घЅҫ ԩ‫ݶ‬ҵ% % ‫ݗ‬Ҵ 5,724.4 100.0% 5,394.9 100.0% 6.1% уռ‫ݗ‬Ҵ 4,933.5 86.2% 4,553.5 84.4% 8.3% BDՂҾє‫ݗ‬Ҵ 790.9 13.8% 841.4 15.6% (6.0%) ଵֈ‫ޯۉ‬ (1,539.8) (26.9%) (1,476.1) (27.4%) 4.3% ଵֈચ࣐ (1,917.4) (33.5%) (1,754.2) (32.5%) 9.3% ॡࣂચ࣐ (370.8) (6.

46. Slide 46: Disclaimer

    ‫ރב‬ Disclaimer • ‫ࡎؐז‬望澝ஐଚы۪‫҈ݕ‬ы‫ކߎث‬ўӄ‫ކͧؠ‬ўӄ‫ؠ‬у߄Օਈԕ‫ܬ‬ӹ䨶‫ۅ‬ஐଚ֮ͨЉҟӟ‫ޢ‬ॐ۪௳ॐङґચ澝‫۪ޢג‬ஐଚͧԕ‫ܬ‬ѸЉஒй͹ߎӄ‫ث୓ؠ‬ОѠ۞ࣔؔऩङ৲Ҽйӄ‫ؠ‬ ۱Ӏ߄ङՃ‫ۅޞ‬澝ପऀ‫ۅ‬澝তे‫ۅ‬ङ‫۪ͫޢג‬ৱҼй҅ऀߎ‫ކ‬ўӄ‫ؠ‬۱ੂ‫ڱ‬Ғ‫ޗێ‬નՕҒङ‫ͨޢג‬澞‫߄֜ײ‬Ҽӄ‫֨؂ؠ‬୪ન澝଴ࢥ۪‫ע‬ӕФ‫ה‬৲‫ږ‬ਚङ੧О۪ৈߧͫ‫ࡎؐז‬望澝ஐ ଚы۪‫҈ݕ‬ы‫࠴ث‬Љ‫ુܛ܈‬Ѡ澞 • ߎ‫ކ‬ўՃҿИ۱ԕխӄ‫ؠ‬ङ۱߄ߓӯԕ‫ࡎؐזं֮ߓ࣍ܬ‬望ࣞ‫؟‬۱߄ͫҿИबҼङ“He

47. Slide 47: © 2025 Henlius.

    @ Henlius #2 ARIE ANE (HA RA oe Reliable Quality Affordable Innovation

Shanghai Henlius Biotech — FY2024 Earnings Presentation on 6ix